Latest News - Clinical Trials

Friday, June 01, 2018

BrainStorm to Host Phone Discussion of Right to Try Legislation and Stem Cell Therapy June 7th

Brainstorm Cell Therapeutics Inc (New York, NY) will host a phone call on June 7th at 8:15 AM EDT to provide interested parties an opportunity to engage with the company regarding new “right-to-…

Read the full story

Tuesday, April 24, 2018

First Results in Humans for Antisense Oligonucleotide Treatment of Patients with Huntington’s Disease

At the American Academy of Neurology meeting in Los Angeles, researchers Sarah Tabrizi, Blair Leavitt, Holly Kordasiewicz, and others presented their results using antisense oligonucleotides (ASO) (IO…

Read the full story

Thursday, March 22, 2018

Phase 3 Clinical Trial Shows Siponimod Significantly Improved Outcomes in Patients With Secondary Progressive Multiple Sclerosis

Results from the phase 3 clinical trial, EXPAND, studying oral, once-daily siponimod (Novartis; East Hanover, NJ) for treatment of secondary progressive multiple sclerosis (SPMS) were published today …

Read the full story

Tuesday, March 20, 2018

Global Alzheimer's Platform Foundation Partners with Lyft to Provide Free Transportation to Research Sites for Clinical Trial Participants

In partnership with Lyft (San Francisco, CA), the Global Alzheimer's Platform Foundation (GAP) (Washington, DC) is beginning a pilot program to provide free transportation to and from research sit…

Read the full story

Wednesday, March 14, 2018

Results From Cannabidiol Dose-Ranging Safety Trial for Treating Patients With Dravet Syndrome

Previous randomized controlled trials have suggested that orally administered cannabidiol (CBD) is effective as an add-on to existing antiepileptic drugs (AEDs) for the treatment of convulsive seizure…

Read the full story

Tuesday, March 06, 2018

First Patient Enrolled in Phase 3 Clinical Trial of Rimegepant for Acute Migraine Treatment

Biohaven Pharmaceutical (New Haven, CT) announced today the first patient enrollment in their phase 3 clinical trial of rimegepant (Zydis) for the acute treatment of migraine.  Zydis is an orally…

Read the full story

Wednesday, February 07, 2018

Phase 3 Trial of P2B001 for Early-Stage Parkinson's Disease Begins With First Patients Receiving First Dose

The drug P2B001(Pharma Two B) is a combination product of pramipexole 0.6mg and rasagiline 0.75 mg given together once daily. Rasagiline is a monoamine oxidase inhibitor used to treat Parkinson&r…

Read the full story

Tuesday, February 06, 2018

Food and Drug Administration Grants Breakthrough Therapy Designation for ZX008 for Treatment of Dravet Syndrome

Low-dose fenfluramine (ZX008, Zogenix) is classified as an orphan drug for the treatment of two rare forms of epilepsy: Dravet syndrome and Lennox-Gastaut syndrome. Positive results from the first piv…

Read the full story

Thursday, February 01, 2018

Post Hoc Clinical Trials Data for Cladribine, An Investigational Oral Multiple Sclerosis Treatment

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, announced that new clinical trial data is being released during the Americas Committee for Treatment and Research in Multi…

Read the full story

Thursday, January 25, 2018

First Prospective Registry Shows Efficacy of Neuromodulation of the Sphenopalatine Ganglion for Treating Cluster Headache

On January 25, 2018, The Journal of Headache and Pain published one-year results from an open-label registry trial, Pathway R-1, evaluating the efficacy of sphenopalatine-ganglion stimulation (SPGs) (…

Read the full story

Monday, January 08, 2018

PROMISE Phase 3 Trial for Chronic Migraine Prevention Meets Primary and All Key Secondary Endpoints; Shows Reduction in Migraine Risk

January 8, 2018--Alder Biopharmaceutical reported that their injectable calcitonin-gene-related peptide (CGRP)-inhibitor eptinezumab, in phase 3 clinical trials, reduced monthly migraine days by 50% o…

Read the full story

Friday, October 27, 2017

ECTRIMS: First-in-Class Monoclonal Antibody Shows Promise in Phase 2 Data

Results from the Phase 2 SYNERGY trial suggest that the investigational opicinumab (Biogen) could have an increased clinical effect in patients with relapsing multiple sclerosis (MS) who had the disea…

Read the full story

Tuesday, August 29, 2017

AstraZeneca and Takeda Strike $400 Million Development Deal for Investigational Parkinson’s Agent

AstraZeneca and Takeda Pharmaceutical Company Limited will jointly develop and commercialize an investigational alpha-synuclein antibody currently in development for the treatment of Parkinson’s…

Read the full story

Tuesday, March 28, 2017

Ocrevus Receives FDA Greenlight for Relapsing, Primary Progressive Forms of Multiple Sclerosis

The FDA has approved Ocrevus (ocrelizumab, Roche/Genentech) for the treatment of both relapsing and primary progressive forms of multiple sclerosis. Ocrelizumab is a humanized antibody that …

Read the full story